Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch

Table 2 Comparison within the tenofovir amibufenamide group after treatment, mean ± SE

TMF	0 week	96 weeks	(0 week vs 96 weeks)
WBC	6.08 ± 0.26	6.53 ± 0.28	0.247149198
Hb	149.46 ± 2.45	149.21 ± 2.78	0.944983486
PLT	207.67 ± 12.31	213.10 ± 11.67	0.74947324
ALT	112.12 ± 13.01	23.48 ± 2.31	3.09 × 10-9
AST	73.10 ± 8.91	23.22 ± 1.21	4.05 × 10-7
Cr	65.37 ± 2.22	74.05 ± 2.12	0.006031745
CLCR	117.91 ± 3.98	100.63 ± 3.44	0.001543066
PHOS	1.05 ± 0.03	0.88 ± 0.02	1.82 × 10-5
GLU	5.06 ± 0.14	5.65 ± 0.42	0.186321806
TG	1.03 ± 0.06	1.29 ± 0.13	0.069367579
CHOL	4.76 ± 0.19	4.64 ± 0.14	0.613234644
HDL	1.46 ± 0.06	1.37 ± 0.07	0.35635419
LDL	2.74 ± 0.14	2.95 ± 0.13	0.276270192
FIB-4	1.52 ± 0.22	1.28 ± 0.24	0.475793108
CAP	201.38 ± 5.99	202.80 ± 6.26	0.870684054
miR3	5.40 ± 0.34	2.41 ± 0.42	4.27 × 10-7
RNA	4.18 ± 0.44	0.53 ± 0.23	5.19 × 10-10
DNA	6.67 ± 0.21	0.27 ± 0.16	1.69 × 10-28
HBsAg	2.88 ± 0.14	2.94 ± 0.10	0.696890055
HBeAg	0.85 ± 0.31	-0.15 ± 0.18	0.005855419

TMF: Tenofovir amibufenamide; WBC: White blood cells; Hb: Hemoglobin; PLT: Platelet; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; Cr: Creatinine; CLCR: Creatinine clearance; PHOS: Phosphorus; GLU: Glucose; TG: Triglycerides; CHOL: Cholesterol; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; FIB-4: Fibrosis-4; CAP: C-reactive protein; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; miR3: Hepatitis B virus-microRNA-3.